4th Quarter - Amendment

COVIDIEN LP for COVIDIEN LP

Firm
Client
Income
—
Expenses
$530,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 21, 2014 $450,000 Replaced
4th Quarter - Amendment (this page) Apr 21, 2014 $530,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Economics/Economic Development ECN

H.R. 2052/S. 1023: Global Investments in American Jobs Act of 2013 (all provisions)

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2052 (113th), S. 1023 (113th)

Taxation/Internal Revenue Code TAX

S. 232: Medical Device Access and Innovation Protection Act (all provisions) ; H.R. 523: Protect Medical Innovation (all provisions); Issues related to the implementation of the Medical Device Tax; Issues related to the repeal of the Medical Device Tax; International tax on foreign direct investment; Corporate Tax Reform generally; S. 95: Student Loan Affordability Act of 2013 (provisions pertaining to international tax).

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —
TIMOTHY MCBRIDE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 523 (113th), S. 95 (113th), S. 232 (113th)

Health Issues HCR

Issues relating to sequestration of the medical device user fees; Issues related to reimbursements for Transcutaneous Electronic Stimulation (TENS) therapy for chronic low back pain; Issue regarding the Hospital Outpatient Prospective Payment System and the proposed changes to the reimbursement of certain vascular procedures. Issues related to SGR legislation and the provision to create a CMS pilot program to encourage more home-based remote monitoring.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —
TIMOTHY MCBRIDE —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.